Figure 3.
Probabilistic sensitivity analysis. (a) Cost-effectiveness acceptable curves show the cost-effective probabilities of T-DXd at different WTP thresholds. The dark dotted lines represent the WTP thresholds. (b) Scatterplot of 10,000 Monte Carlo simulations shows low probability of cost-effectiveness.
QALY, quality-adjusted life-year; T-DXd, trastuzumab deruxtecan; WTP, willingness-to-pay.
